A study published in mAbs reveals that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets, a serious concern for patient safety. The Membrane Proteome Array technology helped identify this issue, challenging the long-held belief in absolute antibody specificity.
Researchers at Integral Molecular have developed highly specific antibodies against Claudin 6, a tumor-specific protein found in multiple solid tumors. The antibodies use a single atomic contact point to derive exquisite specificity, allowing them to target cancer cells while avoiding healthy tissues.
Integral Molecular has developed a panel of fully humanized P2X7 antibodies against autoimmune disorders like atopic dermatitis and glomerulonephritis. The company's MPS Antibody Discovery platform successfully isolated high-affinity antibodies with antagonist or rare agonist activity.
Integral Molecular to receive up to $5.5 million from NIAID to study antibody responses to Zika, Marburg and EEV viruses. The company's Shotgun Mutagenesis technology will aid in the discovery of vaccines and therapeutics against these deadly viruses.
The company has isolated rare inhibitory MAbs against CB1 using its MPS Antibody Discovery platform, offering a therapeutic solution for NASH. With over 10 million people affected in the US, this development could bring new hope to those suffering from liver disease and metabolic disorders.
Artist Heather Dewey-Hagborg collaborated with scientists to create a custom virus that increases oxytocin production, associated with feelings of love and empathy. The 'Lovesick' virus is a harmless, non-replicating vector that expresses the hormone oxytocin and a fluorescent protein, allowing cells to glow bright red.